Monograph Details
|
|
Central Nervous System
> Parkinsonism
|
|
COMTAN |
| Manufacturer |
|
Novartis Pharmaceuticals Corp |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
COMT inhibitor. |
| Generic Name |
|
Entacapone 200mg; tabs. |
| Indications |
|
Adjunct to levodopa/ carbidopa in patients with idiopathic Parkinson's disease and end-of-dose wearing off. |
| Children |
|
Not applicable. |
| Adults |
|
200mg with each dose of levodopa/carbidopa, up to 8 times daily. |
| Precautions |
|
Dyskinesias. Hepatic impairment. Biliary obstruction. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Nonselective MAOIs: not recommended. Consider reducing levodopa dose. Potentiates CNS depression with alcohol, other CNS depressants. Chelates iron. Cardiac effects with drugs metabolized by COMT (e.g., epinephrine, isoproterenol, dopamine, dobutamine, methyldopa, apomorphine, bitolterol). Caution with drugs that interfere with biliary excretion, glucuronidation, intestinal beta-glucuronidase (e.g., probenecid, cholestyramine, erythromycin, rifampicin, ampicillin, chloramphenicol). |
| Adverse Reactions |
|
Dyskinesia, nausea, urine discoloration, hyperkinesia, diarrhea, GI disturbances, back pain, dyspnea, somnolence, anxiety, sweating, purpura, asthenia, taste perversion; rarely: orthostatic hypotension, syncope, hallucinations, rhabdomyolysis, hyperpyrexia and confusion upon withdrawal. |
| How Supplied |
|
Tabs—10, 100, 500 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
